Top Markets
Coin of the day
AIkido Pharma Inc. AIkido Pharma Inc.

AIkido Pharma Inc.

AIKI
Rangering i aksjer #29994
AIkido Pharma Inc., established in 1967 and headquartered in New York, New... AIkido Pharma Inc., established in 1967 and headquartered in New York, New York, is a biotechnology company primarily engaged in pioneering small-molecule anti-cancer treatments. The firm, which operated as Spherix Incorporated until its rebranding in March 2021, possesses a robust therapeutic pipeline addressing various malignancies, including prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. Key drug candidates in its development portfolio include DHA-dFdC, targeting pancreatic cancer, and KPC34, a small molecule designed for the treatment of both AML and acute lymphoblastic leukemia. Furthermore, AIkido Pharma Inc. is advancing an antiviral platform engineered to hinder the proliferation of numerous viruses, such as the influenza virus, Ebolavirus, Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. The company holds strategic license agreements with several academic and research institutions, including the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences.
Aksjekurs
$3.56
Sist synkronisert: 2022-12-21
Markedsverdi
$18.70M
Endring (1 dag)
0.28%
Endring (1 år)
0.00%
Land
US
Handel AIkido Pharma Inc. (AIKI)

Kategori

Inntekter for AIkido Pharma Inc. (AIKI)
Inntekter i 2026 TTM: 0
Ifølge AIkido Pharma Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for AIkido Pharma Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
- -
KR